Capital International Inc. CA Invests $2.47 Million in Juno Therapeutics, Inc. (NASDAQ:JUNO)

Capital International Inc. CA purchased a new stake in Juno Therapeutics, Inc. (NASDAQ:JUNO) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 55,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,467,000.

Several other institutional investors have also recently modified their holdings of the company. Utah Retirement Systems raised its holdings in Juno Therapeutics by 1.8% during the second quarter. Utah Retirement Systems now owns 11,600 shares of the biopharmaceutical company’s stock worth $347,000 after acquiring an additional 200 shares in the last quarter. State of Wisconsin Investment Board increased its position in Juno Therapeutics by 1.7% during the second quarter. State of Wisconsin Investment Board now owns 12,562 shares of the biopharmaceutical company’s stock worth $375,000 after buying an additional 210 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in Juno Therapeutics by 7.2% during the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 228 shares during the last quarter. Aperio Group LLC increased its position in Juno Therapeutics by 4.2% during the third quarter. Aperio Group LLC now owns 29,554 shares of the biopharmaceutical company’s stock worth $1,326,000 after buying an additional 1,194 shares during the last quarter. Finally, SG Americas Securities LLC increased its position in Juno Therapeutics by 9.5% during the third quarter. SG Americas Securities LLC now owns 15,254 shares of the biopharmaceutical company’s stock worth $684,000 after buying an additional 1,328 shares during the last quarter. Institutional investors own 70.37% of the company’s stock.

In related news, EVP Robert Azelby sold 6,666 shares of the firm’s stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $54.95, for a total value of $366,296.70. Following the transaction, the executive vice president now owns 79,998 shares of the company’s stock, valued at approximately $4,395,890.10. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Sunil Agarwal sold 7,285 shares of Juno Therapeutics stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $44.76, for a total transaction of $326,076.60. The disclosure for this sale can be found here. Company insiders own 15.08% of the company’s stock.

Shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) opened at $44.68 on Friday. The company has a quick ratio of 4.77, a current ratio of 4.77 and a debt-to-equity ratio of 0.01. Juno Therapeutics, Inc. has a 1-year low of $17.52 and a 1-year high of $63.45.

Juno Therapeutics (NASDAQ:JUNO) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.80) by $0.07. The firm had revenue of $44.80 million during the quarter, compared to the consensus estimate of $18.12 million. Juno Therapeutics had a negative return on equity of 32.54% and a negative net margin of 332.05%. The business’s revenue was up 115.4% compared to the same quarter last year. During the same period last year, the business posted ($0.57) EPS. analysts anticipate that Juno Therapeutics, Inc. will post -4.02 earnings per share for the current fiscal year.

Several equities analysts have recently commented on the company. Maxim Group set a $56.00 target price on Juno Therapeutics and gave the company a “buy” rating in a research report on Wednesday. Raymond James Financial reissued a “buy” rating on shares of Juno Therapeutics in a research report on Monday, December 11th. Wells Fargo & Company downgraded Juno Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, December 12th. Zacks Investment Research downgraded Juno Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th. Finally, Cowen restated a “buy” rating on shares of Juno Therapeutics in a research note on Friday, November 3rd. Three analysts have rated the stock with a sell rating, eight have given a hold rating and eight have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $45.48.

COPYRIGHT VIOLATION WARNING: This article was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://ledgergazette.com/2017/12/17/55000-shares-in-juno-therapeutics-inc-juno-purchased-by-capital-international-inc-ca.html.

Juno Therapeutics Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Institutional Ownership by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply